RT Journal Article
SR Electronic
T1 Concentrations and immunostimulatory potential of circulating cell-free membrane-bound and membrane-unbound mitochondrial DNA in preeclampsia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.02.21250841
DO 10.1101/2021.02.02.21250841
A1 Spencer C. Cushen
A1 Contessa A. Ricci
A1 Jessica L. Bradshaw
A1 Talisa Silzer
A1 Alexandra Blessing
A1 Jie Sun
A1 Sabrina M. Scroggins
A1 Mark K. Santillan
A1 Donna A. Santillan
A1 Nicole R. Phillips
A1 Styliani Goulopoulou
YR 2021
UL http://medrxiv.org/content/early/2021/02/05/2021.02.02.21250841.abstract
AB Cell-free circulating mitochondrial DNA (CFCmtDNA) is a damage-associated molecular pattern (DAMP) that can activate Toll-like receptor 9 (TLR-9). The main objectives of this case-control study were 1) to determine absolute concentrations and immunostimulatory capacity of CFCmtDNA, in membrane-bound and -unbound states, in cases with preeclampsia and healthy controls and 2) to implement a bootstrapped penalized regression analysis to establish the contribution of CFCmtDNA to preeclampsia diagnosis and its interaction with commonly collected patient characteristics. To determine the contribution of membrane-bound and -unbound CFCmtDNA in preeclampsia, DNA from plasma samples was exctracted with lysis buffer (membrane-unbound) and without lysis buffer (membrane-bound). CFCmtDNA, quantified using absolute PCR quantification protocol, was reduced in preeclampsia compared to healthy controls (P≤0.02). While the pattern of reduced CFCmtDNA in preeclampsia was similar between methods of DNA extraction, DNA isolation with membrane lysis buffer resulted in 1,000-fold higher CFCmtDNA quantification in the preeclampsia group (P=0.0014) and 430-fold higher CFCmtDNA quantification in the control group (P<0.0001). Even though CFCmtDNA concentrations were reduced, plasma from women with preeclampsia induced greater TLR-9 activation than plasma from gestational age matched controls (P≤0.01) as monitored using SEAP reporter 293 cells expressing human TLR-9. Penalized regression analysis showed that women with preeclampsia are strongly likely to have high concentrations of nDNA and DNase I along with a prior history of preeclampsia. Low concentrations of CFCmtDNA and mode of delivery were also associated with preeclampsia. In conclusion, our data demonstrate increases in the immunostimulatory potential of CFCmtDNA and upregulation of DNA degradation mechanisms in women with preeclampsia at the third trimester.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a case control study, in which no human subject was prospectively assigned to one or more interventions. Thus, it does not fall under the definition of clinical trial.Funding StatementThis research was supported in part by the American Heart Association (19TPA34850131 (SG), 18PRE33960162 (SC), 18SCG34350001 (MKS, 19IPLOI34760288 (MKS)), the National Institutes of Health (HL0146562 (SG), UL1TR002537 (DAS, MKS), HD089940 (MKS), HD000849 (MKS), RR024980 (MKS), T32 AG 020494 (SC)), and March of Dimes (#4-FY18-851 to MKS). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:De-identified subject information and blood samples were acquired from the Maternal Fetal Tissue Bank (Study number 200910784) at the University of Iowa. The present study was reviewed by the Institutional Review Board of the University of North Texas Health Science Center, which determined the protocol to meet criteria for exempt status (Study number 2017065).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author.